UBS Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-71,942
| Closed | -$5.41M | – | 11744 |
|
|
2022
Q2 | $5.41M | Sell |
71,942
-2,291
| -3% | -$102K | ﹤0.01% | 2310 |
|
|
2022
Q1 | $1.99M | Sell |
74,233
-46,405
| -38% | -$1.56M | ﹤0.01% | 3428 |
|
|
2021
Q4 | $5.75M | Buy |
120,638
+83,495
| +225% | +$3.73M | ﹤0.01% | 2675 |
|
|
2021
Q3 | $2.47M | Buy |
37,143
+28,894
| +350% | +$2.06M | ﹤0.01% | 3399 |
|
|
2021
Q2 | $643K | Sell |
8,249
-33,543
| -80% | -$2.48M | ﹤0.01% | 4539 |
|
|
2021
Q1 | $3.95M | Buy |
41,792
+41,006
| +5,217% | +$4.88M | ﹤0.01% | 2863 |
|
|
2020
Q4 | $96K | Sell |
786
-1,319
| -63% | -$145K | ﹤0.01% | 5719 |
|
|
2020
Q3 | $184K | Buy |
2,105
+763
| +57% | +$53.2K | ﹤0.01% | 4839 |
|
|
2020
Q2 | $87K | Sell |
1,342
-5,010
| -79% | -$289K | ﹤0.01% | 5413 |
|
|
2020
Q1 | $283K | Sell |
6,352
-14,023
| -69% | -$745K | ﹤0.01% | 4440 |
|
|
2019
Q4 | $1.27M | Sell |
20,375
-6,739
| -25% | -$321K | ﹤0.01% | 3984 |
|
|
2019
Q3 | $1.02M | Buy |
27,114
+25,022
| +1,196% | +$1.09M | ﹤0.01% | 3951 |
|
|
2019
Q2 | $85K | Buy |
+2,092
| New | +$74.6K | ﹤0.01% | 5491 |
|
UBS Group's TPTX Position: Q3 2022 in Review
UBS Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 71,942 shares — an estimated $5.41M sold.
UBS Group first reported a position in TPTX in Q2 2019 and held it in 13 quarters. The position peaked at $5.75M in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.
- UBS Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
- UBS Group sold 71,942 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $5.41M.
- UBS Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
- UBS Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $5.75M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.
Based on UBS Group's 13F filing for Q3 2022, filed 10 Nov 2022.